 |
 |
E-MOVE reports from the 52nd Annual Meeting of the American Academy of Neurology, held in San Diego, California, 30 April-5 May 2000. Citation numbers below refer to abstracts of presentations and posters, which are published in Neurology 2000;54(suppl.3). 1. Long-term effect of pergolide in the treatment of restless legs syndrome K Stiasny, TC Wetter, J Winkelmann, U Brandenburg, T Penzel, M Rubin, WH Oertel, C Trenkwalder S09.002 Twenty-two patients continued on open-label pergolide for RLS after the completion of a double- blind study (http://www.wemove.org/emove/article.asp?ID=49), for a mean follow-up time of 14 months. Mean dose at the end of the study was 0.37 mg/day, and 9 patients required domperidone to control side effects. Periodic limb movement index by polysomnography fell from 48.0 at pre-treatment baseline to 15.4 at the end of the study (p=0.0001). There were also significant improvements in total sleep time, sleep efficiency, and physician-rated clinical global impression. Patients rated their RLS symptoms to be improved compared to baseline, falling from 4.8 to 1.7 on a 10-point severity scale (p=0.0001), and reported continued satisfaction with their sleep quality, rising from 2.4 to 5.7 on a 7-point satisfaction scale (p=0.0001). 2. Ropinirole for restless legs syndrome (RLS) A Freeman, DB Rye, D Bliwise, S Krulewicz, RL Watts S09.003 Eighteen idiopathic RLS patients received open-label ropinirole for 2 weeks, at a mean dose of 1.8 mg/day (range 0.25-6 mg). Twelve patients showed moderate-to-marked improvement on the International RLS rating scale, 5 showed minimal improvement, and 1 was worse. Group mean reduction on the RLS disability scale was 44% (p<0.001). Copyright 2000 WE MOVE Editor: Richard Robinson ([log in to unmask]) This service is provided free of charge to the Internet community, courtesy of WEMOVE.org. This document may be freely redistributed by email only in its unedited form. We encourage you to share it with your colleagues. E-MOVE archives, plus information on subscribing, are available at http://www.wemove.org/emove. To unsubscribe, send an e-mail to [log in to unmask], with "unsubscribe e-move" in the message body. E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for Movement Disorders) 204 West 84th Street New York, NY 10024 TEL 800-437-MOV2 TEL 212-241-8567 FAX 212-987-7363 http://www.wemove.org janet paterson 53 now / 41 dx / 37 onset a new voice: http://www.geocities.com/janet313/ 613 256 8340 PO Box 171 Almonte Ontario Canada K0A 1A0